Acute coronary syndrome: the struggle for the best in risk stratification and therapy.

on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 412–7. [9] Brull DJ, Sanders J, Rumley A et al. Statin therapy and the acute inflammatory response after coronary artery bypass grafting. Am J Cardiol 2001; 88: 431–3. [10] Liuzzo G, Rizzello V. C-reactive protein and primary prevention of ischemic heart disease. Clin Chim Acta 2001; 311: 45–8. [11] Bristow MR, Ginsburg R, Umans V et al. B1 and B2 adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective B1 receptor down-regulation in heart failure. Circ Res 1986; 59: 297– 309. [12] Hall JA, Petch MC, Brown MJ. In vivo demonstration of cardiac beta 2 adrenoreceptor sensitization by beta 1 antagonist treatment. Circ Res 1991; 69: 959–64. [13] von Kanel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on haemostasis in vivo. Eur J Haematol 2000; 65: 357–69.